aTyr Shares Plummet 80% After Failed Trial; Hagens Berman Investigates
aTyr Pharma, Inc. (NASDAQ: ATYR) shares plummeted over 80% on September 15, 2025, following the failure of its late-stage efzofitimod trial for treating pulmonary sarcoidosis. The disappointing result has sparked an investigation by national shareholders rights firm Hagens Berman, focusing on the propriety of aTyr's disclosures about its Phase 2 data and Phase 3 trial design.
Hagens Berman is urging investors who suffered significant losses to submit their claims now. The firm is investigating whether aTyr may have misled investors by previously assuring them that its Phase 2 data was exceptional and efzofitimod could dominate the multi-billion-dollar ILD market. The failed Phase 3 EFZO-FIT trial has cast doubt on these earlier claims, leading to a brutal market response with shares down over 80%. Hagens Berman, with a track record of securing over $2.9 billion in similar cases, is also encouraging persons with knowledge to assist in the investigation.
The investigation is ongoing, focusing on aTyr's disclosures about its Phase 2 efzofitimod data and Phase 3 EFZO-FIT trial design. Investors who suffered losses and persons with relevant knowledge are urged to come forward. The outcome of this investigation could have significant implications for aTyr and its investors.
Read also:
- Orioles' 2025 Turnaround Powered by Late-Season Pitching Acquisitions
- The Cost of Speech is Zero, True Strength Lies in Unity
- Beginning a Food Truck Venture: Crucial Stages to Achieve Profitability
- Aiming to simplify the move towards cleaner automobiles, the newly established ministry plans to take direct action with Pannier-Runacher, Létard, and Vautrin at the helm.
